A three-arm phase III randomised trial assessing, in patients with extensive-disease small-cell lung cancer, accelerated chemotherapy with support of haematological growth factor or oral antibiotics

The European Lung Cancer Working Party (ELCWP) designed a 3-arm phase III randomised trial to determine the role of accelerated chemotherapy in extensive-disease (ED) small-cell lung cancer (SCLC). Eligible patients were randomised between the 3 following arms: (A) Standard chemotherapy with 6 cours...

Descripción completa

Detalles Bibliográficos
Autores principales: Sculier, J P, Paesmans, M, Lecomte, J, Van Cutsem, O, Lafitte, J J, Berghmans, T, Koumakis, G, Florin, M C, Thiriaux, J, Michel, J, Giner, V, Berchier, M C, Mommen, P, Ninane, V, Klastersky, J
Formato: Texto
Lenguaje:English
Publicado: Nature Publishing Group 2001
Materias:
Regular Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2363948/
https://www.ncbi.nlm.nih.gov/pubmed/11720426
http://dx.doi.org/10.1054/bjoc.2001.2114

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2363948/
https://www.ncbi.nlm.nih.gov/pubmed/11720426
http://dx.doi.org/10.1054/bjoc.2001.2114

Ejemplares similares